Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 11:11:549272.
doi: 10.3389/fpsyt.2020.549272. eCollection 2020.

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine

Christopher K Blazes  1 , Jonathan D Morrow  1   2
Affiliations

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine

Christopher K Blazes et al. Front Psychiatry. .
No abstract available

Keywords: addiction; agonist therapy; diversion; opioids; overdose; substance use disorders.

PubMed Disclaimer

References

    1. National Center for Health Statistics Health, United States, 2017: With Special Feature on Mortality. Hyattsville, Maryland: Centers for Disease Control and Prevention; (2018). - PubMed
    1. Walsh L. Buprenorphine. Available at: https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorp... (Accessed August 1, 2019). Published June 15, 2015.
    1. Volpe DA, McMahon Tobin GA, Mellon RD, Katki AG, Parker RJ, Colatsky T, et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol RTP (2011) 59(3):385–90. 10.1016/j.yrtph.2010.12.007 - DOI - PubMed
    1. Lee KO, Akil H, Woods JH, Traynor JR. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol (1999) 378(3):323–30. 10.1016/S0014-2999(99)00460-4 - DOI - PubMed
    1. Neilan CL, Husbands SM, Breeden S, Holden Ko MC, Aceto MD, Lewis JW, et al. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. Eur J Pharmacol (2004) 499(1-2):107–16. 10.1016/j.ejphar.2004.07.097 - DOI - PubMed

LinkOut - more resources